Clinical Trial Update: S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating S1 plus Anlotinib in patients with refractory or relapsed small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• S1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Taizhou Hospital | Conditions: Small Cell Lung Cancer Recurrent | Phase 2 | Status: COMPLETED